January 31, 2020 08:37 AM ESTUpdated 12:22 PM
Peer Review

Mod­er­na woos tri­al vet Melanie Ivars­son to the se­nior R&D team; Ex-Roche CMO San­dra Horn­ing joins Gilead board

Kathy Wong

Editor

Mod­er­na was found­ed 10 years ago and ear­ly on grew in­to a uni­corn with grand am­bi­tions for a broad pre­clin­i­cal ef­fort in mes­sen­ger RNA. Now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times